Lumos Diagnostics Lands US$1.3M FebriDx® Order After FDA Boost
Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.
- Largest FebriDx® purchase order valued at US$1.3 million
- Order placed by US exclusive distributor PHASE Scientific
- Follows FDA 510(k) clearance with CLIA waiver granted in March 2026
- Market opportunity expanded to over US$1 billion in the US
- Order validates commercial potential in urgent and primary care settings
FDA Clearance Unlocks Major US Market
Lumos Diagnostics Holdings Ltd (ASX:LDX) has taken a significant step forward in commercialising its rapid diagnostic test, FebriDx®, in the United States. The company announced it has received its largest purchase order to date, valued at US$1.3 million, from its US exclusive distributor PHASE Scientific. This milestone follows the recent US Food and Drug Administration (FDA) 510(k) clearance with a Clinical Laboratory Improvement Amendments (CLIA) waiver granted on 27 March 2026.
The FDA clearance is a game-changer for Lumos, expanding the addressable US market for FebriDx® by 15 times to over US$1 billion. The CLIA waiver means the test can be used in a wider range of healthcare settings, including urgent care clinics and primary care offices, where rapid and accurate diagnosis is critical.
Commercial Validation and Growth Prospects
Doug Ward, CEO of Lumos Diagnostics, described the order as a strong validation of FebriDx®’s commercial opportunity in the US. The sizeable purchase order from PHASE Scientific underscores growing confidence in the product’s potential to meet urgent diagnostic needs. As PHASE scales its commercial rollout, Lumos is positioned to benefit from increased adoption across a broader spectrum of healthcare providers.
FebriDx® is designed to rapidly differentiate between bacterial and viral respiratory infections, a capability that can reduce unnecessary antibiotic prescriptions and improve patient outcomes. The expanded market access following FDA clearance is expected to accelerate sales momentum and enhance Lumos’s footprint in the competitive point-of-care diagnostics sector.
Looking Ahead
While the announcement marks a significant commercial milestone, details on the timing of revenue recognition and future sales forecasts remain to be disclosed. Investors will be watching closely for updates on PHASE’s rollout progress and any further regulatory developments that could influence Lumos’s growth trajectory.
Overall, this order signals a promising chapter for Lumos Diagnostics as it leverages regulatory approvals to unlock substantial market opportunities in the US healthcare landscape.
Bottom Line?
Lumos’s FDA clearance and record FebriDx® order set the stage for a pivotal growth phase in the US market.
Questions in the middle?
- How quickly will PHASE Scientific scale FebriDx® distribution across US healthcare settings?
- What are the expected revenue timelines and margins from this US market expansion?
- Could further regulatory approvals or partnerships accelerate Lumos’s global growth?
